- Report
- October 2024
- 181 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- August 2024
- 100 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 89 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- January 2025
- 880 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- February 2025
- 183 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- May 2024
- 132 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- December 2024
- 180 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Clinical Trials
- December 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Clinical Trials
- June 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP

The Non Small Cell Lung Cancer Drug market is a subset of the larger Lung Cancer Drug market. Non Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. NSCLC is typically treated with chemotherapy, radiation, and targeted therapies. Targeted therapies are drugs that target specific molecules involved in the growth and spread of cancer cells. These drugs are designed to block the growth and spread of cancer cells while limiting damage to healthy cells.
The Non Small Cell Lung Cancer Drug market is highly competitive, with a number of companies offering various treatments. Companies such as AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer are some of the major players in the market. Other companies such as Amgen, Boehringer Ingelheim, and Novartis are also active in the market. Show Less Read more